Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT03728829 |
Other study ID # |
YLiu |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
July 2021 |
Est. completion date |
December 31, 2022 |
Study information
Verified date |
July 2021 |
Source |
Hebei Medical University Fourth Hospital |
Contact |
Yunjiang Liu, MD, PhD |
Phone |
+86-311-8609-5588 |
Email |
lyj818326[@]126.com |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
To explore the genetic background of patients with HER2 positive breast cancer that benefit
from trastuzumab combined with neoadjuvant chemotherapy, identify clinically actionable
mutations that associated with trastuzumab resistance or drug efficacy, we designed this
Observational phase II trial. The primary endpoint is genetic profile of HER2+ breast cancer
patients treated with trastuzumab combined neoadjuvant chemotherapy. Secondary endpoints
included pathological complete response (pCR) rate and safety.
Description:
Currently, patients with stage II-III breast cancer still accounts for a large population in
China, and neoadjuvant therapy is considered the standard treatment for them. The
pathological complete response (pCR) rate takes for an indicator for regimens efficacy, and
the achievement of pCR after neoadjuvant chemotherapy is associated with favorable outcomes
including disease-free survival and overall survival.
HER2+ breast cancer represents an invasive and poor prognosis subtype, and the efficacy of
neoadjuvant therapy for these patients has been greatly augmented by the addition of
trastuzumab. However, more than 50% of HER2+ breast cancer patients treated with trastuzumab
combined neoadjuvant chemotherapy cannot achieve pCR, even experience primary drug resistance
and rapid disease progression. Therefore, to explore the genomic features of the population
that benefited from trastuzumab combined with chemotherapy is of great significance for
personalized treatment of HER2+ breast cancer, aiming to avoid overtreatment and identify
clinically actionable mutations for future therapy instructions.